Search Results - "Lunec, John"

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma by Wu, Chiao-En, Esfandiari, Arman, Ho, Yi-Hsuan, Wang, Nan, Mahdi, Ahmed Khairallah, Aptullahoglu, Erhan, Lovat, Penny, Lunec, John

“…Background: Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma. TP53 mutations are rare in…”
Get full text

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner by Esfandiari, Arman, Hawthorne, Thomas A, Nakjang, Sirintra, Lunec, John

“…Sensitivity to MDM2 inhibitors is widely different among responsive TP53 wild-type cell lines and tumors. Understanding the determinants of MDM2 inhibitor…”
Get full text

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition by Aptullahoglu, Erhan, Ciardullo, Carmela, Wallis, Jonathan P, Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John

“…Several molecular subtypes of cancer are highly dependent on splicing for cell survival. There is a general interest in the therapeutic targeting of splicing…”
Get full text

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia by Aptullahoglu, Erhan, Wallis, Jonathan P, Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John

“…Chronic lymphocytic leukemia (CLL) is a genetically and clinically heterogeneous malignancy affecting older individuals. There are a number of current…”
Get full text

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage by Ladds, Marcus J. G. W., van Leeuwen, Ingeborg M. M., Drummond, Catherine J., Chu, Su, Healy, Alan R., Popova, Gergana, Pastor Fernández, Andrés, Mollick, Tanzina, Darekar, Suhas, Sedimbi, Saikiran K., Nekulova, Marta, Sachweh, Marijke C. C., Campbell, Johanna, Higgins, Maureen, Tuck, Chloe, Popa, Mihaela, Safont, Mireia Mayoral, Gelebart, Pascal, Fandalyuk, Zinayida, Thompson, Alastair M., Svensson, Richard, Gustavsson, Anna-Lena, Johansson, Lars, Färnegårdh, Katarina, Yngve, Ulrika, Saleh, Aljona, Haraldsson, Martin, D’Hollander, Agathe C. A., Franco, Marcela, Zhao, Yan, Håkansson, Maria, Walse, Björn, Larsson, Karin, Peat, Emma M., Pelechano, Vicent, Lunec, John, Vojtesek, Borivoj, Carmena, Mar, Earnshaw, William C., McCarthy, Anna R., Westwood, Nicholas J., Arsenian-Henriksson, Marie, Lane, David P., Bhatia, Ravi, McCormack, Emmet, Laín, Sonia

“…The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we…”
Get full text

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells by Ciardullo, Carmela, Aptullahoglu, Erhan, Woodhouse, Laura, Lin, Wei-Yu, Wallis, Jonathan P, Marr, Helen, Marshall, Scott, Bown, Nick, Willmore, Elaine, Lunec, John

“…Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous hematologic malignancy. In approximately 90% of cases the gene is in its wildtype state at…”
Get full text

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers by Wu, Chiao-En, Pan, Yi-Ru, Yeh, Chun-Nan, Lunec, John

“…Gemcitabine-based chemotherapy is the current standard treatment for biliary tract cancers (BTCs) and resistance to gemcitabine remains the clinical challenge…”
Get full text

p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma by LINDI CHEN, IRACI, Nunzio, GHERARDI, Samuele, GAMBLE, Laura D, WOOD, Katrina M, PERINI, Giovanni, LUNEC, John, TWEDDLE, Deborah A

“…MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a…”
Get full text

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage by Ladds, Marcus J. G. W., van Leeuwen, Ingeborg M. M., Drummond, Catherine J., Chu, Su, Healy, Alan R., Popova, Gergana, Fernández, Andrés Pastor, Mollick, Tanzina, Darekar, Suhas, Sedimbi, Saikiran K., Nekulova, Marta, Sachweh, Marijke C. C., Campbell, Johanna, Higgins, Maureen, Tuck, Chloe, Popa, Mihaela, Safont, Mireia Mayoral, Gelebart, Pascal, Fandalyuk, Zinayida, Thompson, Alastair M., Svensson, Richard, Gustavsson, Anna-Lena, Johansson, Lars, Färnegårdh, Katarina, Yngve, Ulrika, Saleh, Aljona, Haraldsson, Martin, D’Hollander, Agathe C. A., Franco, Marcela, Zhao, Yan, Håkansson, Maria, Walse, Björn, Larsson, Karin, Peat, Emma M., Pelechano, Vicent, Lunec, John, Vojtesek, Borivoj, Carmena, Mar, Earnshaw, William C., McCarthy, Anna R., Westwood, Nicholas J., Arsenian-Henriksson, Marie, Lane, David P., Bhatia, Ravi, McCormack, Emmet, Laín, Sonia

Get full text

Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients by Manoharan, Vahinipriya, Karunanayake, Eric Hamilton, Tennekoon, Kamani Hemamala, De Silva, Sumadee, Imthikab, Ahamed Ilyas Ahamed, De Silva, Kanishka, Angunawela, Preethika, Vishwakula, Sameera, Lunec, John

“…Breast cancer (BC) is known to be the most common malignancy in females whereas colorectal cancer (CRC) incidence also higher in both genders in Sri Lanka…”
Get full text

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia by Bell, Hayden L., Blair, Helen J., Singh, Mankaran, Moorman, Anthony V., Heidenreich, Olaf, van Delft, Frederik W., Lunec, John, Irving, Julie A. E.

“…Abstract Background Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve…”
Get full text

Key features of the environment promoting liver cancer in the absence of cirrhosis by Zaki, Marco Youssef William, Mahdi, Ahmed Khairallah, Patman, Gillian Lucinda, Whitehead, Anna, Maurício, João Pais, McCain, Misti Vanette, Televantou, Despina, Abou-Beih, Sameh, Ramon-Gil, Erik, Watson, Robyn, Cox, Charlotte, Leslie, Jack, Wilson, Caroline, Govaere, Olivier, Lunec, John, Mann, Derek Austin, Nakjang, Sirintra, Oakley, Fiona, Shukla, Ruchi, Anstee, Quentin Mark, Tiniakos, Dina, Reeves, Helen Louise

“…The prevalence of obesity and non-alcoholic fatty liver disease (NAFLD) associated hepatocellular carcinoma (HCC) is rising, even in the absence of cirrhosis…”
Get full text

RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia by Aptullahoglu, Erhan, Nakjang, Sirintra, Wallis, Jonathan P, Marr, Helen, Marshall, Scott, Willmore, Elaine, Lunec, John

“…Chronic lymphocytic leukemia (CLL) is a genetically and clinically diverse hematological cancer affecting middle-aged and elderly individuals. Novel targeted…”
Get full text

Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein−Protein Interaction: Structure−Activity Studies Leading to Improved Potency by Hardcastle, Ian R, Liu, Junfeng, Valeur, Eric, Watson, Anna, Ahmed, Shafiq U, Blackburn, Timothy J, Bennaceur, Karim, Clegg, William, Drummond, Catherine, Endicott, Jane A, Golding, Bernard T, Griffin, Roger J, Gruber, Jan, Haggerty, Karen, Harrington, Ross W, Hutton, Claire, Kemp, Stuart, Lu, Xiaohong, McDonnell, James M, Newell, David R, Noble, Martin E. M, Payne, Sara L, Revill, Charlotte H, Riedinger, Christiane, Xu, Qing, Lunec, John

“…Inhibition of the MDM2-p53 interaction has been shown to produce an antitumor effect, especially in MDM2 amplified tumors. The isoindolinone scaffold has…”
Get full text

p53 as a biomarker and potential target in gastrointestinal stromal tumors by Wu, Chiao-En, Chen, Chiao-Ping, Huang, Wen-Kuan, Pan, Yi-Ru, Aptullahoglu, Erhan, Yeh, Chun-Nan, Lunec, John

“…KIT and PDGFRA play a major role in the oncogenic process in gastrointestinal stroma tumors (GIST) and small molecules have been employed with great success to…”
Get full text

Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma by Rankin, Kenneth S., Starkey, Mike, Lunec, John, Gerrand, Craig H., Murphy, Sue, Biswas, Swethajit

“…The similarities between human and canine osteosarcoma with regard to histology, biological behavior and molecular genetic alterations suggest that the dog…”
Get full text

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response by Wu, Chiao-En, Koay, Tsin Shue, Ho, Yi-Hsuan, Lovat, Penny, Lunec, John

“…Emergence of resistance to molecular targeted therapy constitutes a limitation to clinical benefits in cancer treatment. Cross-resistance commonly happens with…”
Get full text

Small-Molecule Inhibitors of the MDM2-p53 Protein−Protein Interaction Based on an Isoindolinone Scaffold by Hardcastle, Ian R, Ahmed, Shafiq U, Atkins, Helen, Farnie, Gillian, Golding, Bernard T, Griffin, Roger J, Guyenne, Sabrina, Hutton, Claire, Källblad, Per, Kemp, Stuart J, Kitching, Martin S, Newell, David R, Norbedo, Stefano, Northen, Julian S, Reid, Rebecca J, Saravanan, K, Willems, Henriëtte M. G, Lunec, John

“…From a set of weakly potent lead compounds, using in silico screening and small library synthesis, a series of 2-alkyl-3-aryl-3-alkoxyisoindolinones has been…”
Get full text

Cell Cycle Regulation Targets of MYCN Identified by Gene Expression Microarrays by Bell, Emma, Lunec, John, Tweddle, Deborah

“…Background: We have previously shown that MYCN knockdown causes a G1 arrest in MYCN amplified (MNA), p53 wild type (wt) and p53 mutant MNA neuroblastoma cell…”
Get full text

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor by Franklin, Miriam, Gentles, Lucy, Matheson, Elizabeth, Bown, Nick, Cross, Paul, Ralte, Angela, Gilkes‐Immeson, Connor, Bradbury, Alice, Zanjirband, Maryam, Lunec, John, Drew, Yvette, O'Donnell, Rachel, Curtin, Nicola J.

“…NUCOLL43 is a novel ovarian clear cell carcinoma (O‐CCC) cell line that arose from a primary culture of a patient's malignant ascites. The cells grow reliably…”
Get full text